RxDoctor Payments Data

Eric Weiner, MD

Pulmonary Disease · Newport News, VANPI 1982601993

Payments from drug & device makers

$6,499in general payments, 2019–2025

Across 59 payments — averaging $110.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Inspire Medical Systems, Inc.$2K
  • AstraZeneca$181
  • Harmony Biosciences LLC$163
  • Itamar Medical Inc$159
  • Paratek Pharmaceuticals, Inc.$145
  • plus $703 from 18 others

What the payments were for

  • Travel & lodging$1,00215%
  • Food & beverage$2,48138%
  • Education$3,01646%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,499 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.

See all pulmonary disease providers in Virginia

Medicare billing

Part B allowed, 2024
$66,337
Medicare patients
515
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter371$311,376
Ambrisentan13$131,973
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr123$59,227
Stiolto RespimatTiotropium Br/Olodaterol Hcl69$46,969
Spiriva RespimatTiotropium Bromide52$36,094
Breo ElliptaFluticasone/Vilanterol51$25,250
SymbicortBudesonide/Formoterol Fumarate55$21,208
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$19,464
Spiriva HandihalerTiotropium Bromide15$10,628
Albuterol Sulfate HfaAlbuterol Sulfate245$7,381
Mycophenolate Mofetil12$3,254
Armodafinil27$2,445
Ventolin HfaAlbuterol Sulfate27$2,057
Roflumilast33$1,489
Levalbuterol Tartrate HfaLevalbuterol Tartrate27$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$33$395,853545 claims
AstraZenecaSymbicort, Breztri Aerosphere$181$40,67287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.

Other pulmonary disease in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →